Key facts
- This page summarizes Adam Schayowitz's Form 4 filing for Zymeworks Inc. (ZYME).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 09 Oct 2026, 18:28.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Sale
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Additional SEC filing notes
Footnote F1
Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on October 9, 2025.
Footnote F2
Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.
Footnote F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.85 to $25.88, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Footnote F4
Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
Footnote F5
Restricted stock units ("RSUs") granted October 9, 2025; vest in three equal annual installments beginning October 9, 2026.